Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections

US11548901B2 · kind B2 · utility

Assignee

• Gilead Sciences, Inc. · US

Inventors

• Elizabeth M. Bacon · Burlingame, US
• Zhenhong R. Cai · Palo Alto, US
• Xiaowu Chen · Hillsborough, US
• Jeromy J. Cottell · Redwood City, US
• Manoj C. Desai · Pleasant Hill, US
• Mingzhe Ji · Xi'an, CN
• Haolun Jin · Foster City, US
• Scott E. Lazerwith · Foster City, US
• Michael R. Mish · Foster City, US
• Philip Anthony Morganelli · Oakland, US
• Hyung-Jung Pyun · Fremont, US
• James G. Taylor · Burlingame, US
• Teresa Alejandra Trejo Martin · Belmont, US

Key dates

• Filing date: May 6, 2020
• Grant date: Jan 10, 2023
• Expiry date: May 6, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.